[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BBRC posts on X about $espr, japan, $4578t, $4768t the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence countries XXXXX% finance XXXXX%
Social topic influence $espr #2, japan #3615, $4578t #6, $4768t #6, listing 9.09%, 1 week 9.09%, market cap 9.09%, combo 9.09%, approved 9.09%, $8750t XXXX%
Top accounts mentioned or mentioned by @macrovet888 @blueeee_jay @blueeeejay @andrearilli
Top posts by engagements in the last XX hours
"$ESPR Product could be on the shelf in Japan within X week of pricing and NHI listing. Otsuka is known to pre-stage inventory. Let's see how this plays out"
X Link @Bbrc424864Bbrc 2025-10-15T01:17Z XXX followers, XXX engagements
"$ESPR Let's say Otsuka was preparing a lowball buyout offer. it makes sense for them to buy ESPR. They owe milestone payments and royalties that exceed the current market cap of the entire company. The stock offering kills two birds with one stone. Makes a low ball offer unlikely to succeed and takes the pressure off any delay in milestone payments"
X Link @Bbrc424864Bbrc 2025-10-10T20:05Z XXX followers, XXX engagements
"$ESPR Tech transfer already underway. It will save $XX million to $XX million. Japan will add $XX million to $XX million. 2026 is looking good. Cash in the bank"
X Link @Bbrc424864Bbrc 2025-10-13T18:12Z XXX followers, XXX engagements
"$ESPR The triple combo patent was recently approved in Japan. If Otsuka wants to license this product they will likely pay between $XX million and $XX million depending on deal scope and exclusivity. If Daiichi Europe wants the triple combo and they do want it expect them to pay $XX million to $XX million depending on deal scope and timing. These are the upfront payments. Contracts likely include royalties just like the current contracts for Nexletol and Nexlizet"
X Link @Bbrc424864Bbrc 2025-10-13T04:20Z XXX followers, XXX engagements
"Many upset with management missteps. Many unhappy with hedge fund short selling manipulation. I get it. But It is a great product. Sales are growing. Profitability is close"
X Link @Bbrc424864Bbrc 2025-10-12T06:24Z XXX followers, XX engagements
"$ESPR Q3 2025 total revenue should be $XX - $XX million. Consensus EPS forecast is $.02 per share. A sharp improvement from -$.15 in Q3 2024"
X Link @Bbrc424864Bbrc 2025-10-12T06:20Z XXX followers, XXX engagements